Contract manufacturer Aesica Pharmaceuticals has made two changes to personnel.
David Greensmith has become non-executive chairman, while Ian Lafferty has been promoted to site director of the firm’s formulation development facility in Nottingham, UK.
Greensmith has relevant experience from operating in the chemical and pharmaceutical markets, as well as through holding a number of private equity backed non-executive chairmanship positions. His previous executive roles include managing director of Fujifilm Imaging Colorants and chief operating officer of Avecia Group.
Lafferty will oversee the continued growth of the site and the increased interest in high potency and biological formulations following the recent expansion of Aesica’s high containment and sterile manufacturing suite.
‘I plan to build on the strong foundations established by the Formulation Development team to ensure that this site plays a pivotal role in the continued growth of Aesica on a global scale,’ said Lafferty.
‘It’s an ideal time to be joining the senior management team and I relish the opportunity to drive the business forward in line with our exciting expansion plans.
‘One of my key goals initially is to attract new strategic partners in the coming months based on our high containment capabilities.’
